Clearmind Medicine Secures International Patent for Therapy
Clearmind Medicine Inc., a pioneering biotech company actively engaged in the development of groundbreaking psychedelic-derived therapeutics, has recently made headlines with its filing for an international patent application. This application, governed by the Patent Cooperation Treaty (PCT), focuses on a cutting-edge combination therapy that merges MEAI (5-methoxy-2-aminoindane) with Palmitoylethanolamide (PEA).
Targeting Global Health Issues
This innovative combination aims to tackle two pressing global health challenges: obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Recent statistics indicate that obesity is a growing concern, affecting approximately 890 million individuals across the globe—making it a leading contributor to various chronic health conditions. Simultaneously, non-alcoholic fatty liver disease, closely tied to metabolic disorders, is estimated to affect over 30% of the adult population worldwide.
Given the scale of these health crises, the need for effective treatment options has never been more critical. The proprietary blend of MEAI and PEA presents a promising alternative that not only addresses these issues but does so with a unique pharmacological approach.
Collaboration With SciSparc Ltd.
Clearmind's commitment to improving health outcomes is encapsulated in its ongoing collaboration with SciSparc Ltd., a clinical-stage pharmaceutical company focused on central nervous system disorders. This partnership signifies Clearmind's dedication to developing therapies that cater to significant medical needs.
What Makes MEAI and PEA Stand Out?
MEAI is recognized for its unique therapeutic properties, while PEA is renowned for its anti-inflammatory and neuroprotective effects. By harnessing the benefits of these two compounds, Clearmind aims to offer a safe and effective treatment pathway, thereby revolutionizing existing approaches to managing obesity and fatty liver disease.
Committed to Innovation
The CEO of Clearmind, Dr. Adi Zuloff-Shani, expressed enthusiasm about this recent patent application, stating, "Our goal is to bring meaningful innovation to areas with high unmet medical need. This patent filing reflects our commitment to developing novel, science-backed treatments that can potentially improve the lives of millions struggling with obesity and fatty liver disease." This commitment underscores Clearmind's strategic mission to bridge the gap in healthcare.
About Clearmind Medicine
Clearmind Medicine Inc. stands at the forefront of psychedelic pharmaceutical innovation, driven by a vision to discover and develop novel therapeutics that address pressing health issues, including alcohol use disorder. The company’s research and development efforts focus on creating regulated psychedelics that can seamlessly integrate into medical practice as medicines, foods, or dietary supplements.
Currently, Clearmind boasts an impressive intellectual property portfolio consisting of nineteen patent families, with 31 granted patents. The company remains proactive in seeking further patents for its innovative compounds while exploring the strategic acquisition of additional intellectual property to enhance its offerings.
Trading and Contact Information
Shares of Clearmind Medicine are actively traded on Nasdaq under the symbol "CMND" and also on the Frankfurt Stock Exchange under the symbol "CWY0." For more insights and updates, investors and interested parties are encouraged to visit the company's website or reach out directly for more information.
For further inquiries, please contact Clearmind’s Investor Relations at invest@clearmindmedicine.com or by telephone at (604) 260-1566. Additional general inquiries can be sent via email to info@clearmindmedicine.com.
Frequently Asked Questions
What is the focus of Clearmind's new patent?
The patent focuses on a combination therapy that includes MEAI and PEA to address obesity and fatty liver disease.
Why is this therapy considered innovative?
This therapy is seen as innovative due to the unique properties of MEAI and PEA, which together aim to provide safer and more effective treatment options.
Which markets does Clearmind operate in?
Clearmind primarily operates in the biotechnology sector, specifically focusing on psychedelic-derived therapeutics with potential applications in various health conditions.
How many patents does Clearmind have?
Clearmind currently holds a portfolio of nineteen patent families, which includes 31 granted patents, showcasing its commitment to innovation.
Where can I find more information about Clearmind Medicine?
More information can be found on Clearmind's official website or by contacting their investor relations department directly.
